Eisai Co., Ltd. (ESAIY)
OTCMKTS · Delayed Price · Currency is USD
7.78
-0.02 (-0.26%)
Aug 28, 2025, 3:35 PM EDT
Eisai Revenue
Eisai had revenue of 202.65B JPY in the quarter ending June 30, 2025, with 7.21% growth. This brings the company's revenue in the last twelve months to 803.02B, up 9.43% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
803.02B JPY
Revenue Growth
+9.43%
P/S Ratio
1.58
Revenue / Employee
73.56M JPY
Employees
10,917
Market Cap
8.81B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Eisai News
- 23 days ago - Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 2 months ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 3 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 6 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 6 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 7 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha